TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23419231

Group type: EXPERIMENTAL
Intervention: Quetiapine 400 mg/d
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/d
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 22379909

Group type: EXPERIMENTAL
Intervention: Isobaric bypivacain (5 mg/ml)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ropivacain (5 mg/ml)
Number of subjects: 38
Study: 19508650

Group type: EXPERIMENTAL
Intervention: Plyometric training (8 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no plyometric training)
Number of subjects: 17
Study: 17845965

Group type: EXPERIMENTAL
Intervention: Total-body screening with multidetector computed tomography
Number of subjects: 50

Group type: COMPARATOR
Intervention: No screening for 3 years
Number of subjects: 50
Study: 15210591

Group type: EXPERIMENTAL
Intervention: Anemia (Hb < or =12.0 g/dL)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Higher baseline hemoglobin (1 g/dL increase)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Increase in hemoglobin over time
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Decrease in hemoglobin over time
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: NYHA classes
Number of subjects: 912
Study: 11202334

Group type: EXPERIMENTAL
Intervention: Laryngographic examination of glottis/neoglottis occlusion effectiveness index in patients post-partial laryngectomy.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (35 subjects).
Number of subjects: 132
Study: 8615506

Group type: EXPERIMENTAL
Intervention: Lansoprazole-lansoprazole (Group L-L)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lansoprazole-placebo (Group L-P)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Placebo-lansoprazole (Group P-L)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Omeprazole-omeprazole (Group O-O)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Omeprazole-placebo (Group O-P)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Placebo-ranitidine (Group P-R)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo-placebo (Group P-P)
Number of subjects: 200
Study: 1410236

Group type: EXPERIMENTAL
Intervention: Family-oriented intervention (Group 3)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Individual intervention (Group 2)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Comparison group (Group 1)
Number of subjects: 168
Study: 4009215

Group type: COMPARATOR
Intervention: Involved field radiation treatment (RTIF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Extended field radiation treatment (RTEF)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (both RTIF and RTEF)
Number of subjects: 108
Study: 30583200

Group type: EXPERIMENTAL
Intervention: Caring (not controlled for positive youth development)
Number of subjects: 2386

Group type: EXPERIMENTAL
Intervention: Caring (controlled for positive youth development)
Number of subjects: 2386
Study: 30286238

Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy for 8 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Face-to-face clinical care (mean of 2 to 3 appointments)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Face-to-face clinical care
Number of subjects: 92
Study: 28003203

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (0-820 mg) with methylxanthines (0-220 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (0-820 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Methylxanthines alone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cocoa flavanols alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols with methylxanthines
Number of subjects: 47
Study: 26408732

Group type: EXPERIMENTAL
Intervention: Directly stopped VEGFR TKI treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continued VEGFR TKI treatment for another two weeks
Number of subjects: 16
Study: 24047919

Group type: EXPERIMENTAL
Intervention: 800 mg Ca/d
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 21437445

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 24

Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Weaning success
Number of subjects: 24

Group type: COMPARATOR
Intervention: Weaning failure
Number of subjects: 24
Study: 18205185

Group type: EXPERIMENTAL
Intervention: Immediate-start zoledronic acid (4 mg intravenously biannually for 5 years)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (4 mg intravenously biannually for 5 years)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Immediate-start zoledronic acid
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid
Number of subjects: 1065
Study: 16443229

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14519799

Group type: EXPERIMENTAL
Intervention: Rectal infusion of acetate (60 mmol/L), propionate (20 mmol/L), and butyrate (20 mmol/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SCFA infused alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Butyrate-containing infusions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infusion of three SCFA
Number of subjects: 10
Study: 11097191

Group type: EXPERIMENTAL
Intervention: Treatment readiness training
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 500
Study: 8630663

Group type: EXPERIMENTAL
Intervention: 4200‐kJ/d diet
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 4200‐kJ/d diet with combined aerobic and anaerobic exercise
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 1417159

Group type: EXPERIMENTAL
Intervention: two annual doses of ivermectin 100 mcg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: three semi‐annual doses of ivermectin 100 mcg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: two annual doses of diethylcarbamazine (DEC) 3 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: three semi‐annual doses of diethylcarbamazine (DEC) 3 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: two annual doses of diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 58
Study: 4074419

Group type: EXPERIMENTAL
Intervention: 35 mg bencyclane intravenously
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 70 mg bencyclane intravenously
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 71 mg bencyclane orally as a solution in water
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 143 mg bencyclane orally as a solution in water
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous bencyclane
Number of subjects: 4
Study: 30890289

Group type: EXPERIMENTAL
Intervention: Linear transducer
Number of subjects: 3

Group type: COMPARATOR
Intervention: Curvilinear transducer
Number of subjects: 3
Study: 30291376

Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy
Number of subjects: 745

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Hyper-inflammatory subphenotype
Number of subjects: 745
Study: 27638496

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 25149143

Group type: EXPERIMENTAL
Intervention: Thoracic sympathetic block (TSB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TSB
Number of subjects: 36
Study: 22624697

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mixture (NOOM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oxygen only (Control)
Number of subjects: 240
Study: 20722555

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 112
Study: 18408611

Group type: EXPERIMENTAL
Intervention: CAF-5 (5 mg.kg(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CAF-3 (3 mg.kg(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CAF-1 (1 mg.kg(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: PL (placebo)
Number of subjects: 40
Study: 15737666

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 4
Study: 12929288

Group type: EXPERIMENTAL
Intervention: Stenting (PCI)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1205
Study: 10830413

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa and bromocriptine
Number of subjects: 31
Study: 8433469

Group type: EXPERIMENTAL
Intervention: Air suspension bed
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard ICU bed
Number of subjects: 100
Study: 2890423

Group type: EXPERIMENTAL
Intervention: ZK 91 296 and ZK 95 962 (high doses, intravenous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZK 95 962
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZK 93 426
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZK 93 426 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZK 93 426 in combination with lormetazepam
Number of subjects: 0
Study: 28084119

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study: 27288603

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry
Number of subjects: 30
Study: 26350611

Group type: EXPERIMENTAL
Intervention: High intensity intermittent training (HIIT) for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard care for 12 weeks
Number of subjects: 28
Study: 23569138

Group type: EXPERIMENTAL
Intervention: Low-protein diet with keto acid supplementation (0.1 g/kg IBW per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-protein diet without keto acid supplementation
Number of subjects: 17
Study: 22173365

Group type: EXPERIMENTAL
Intervention: Nurse practitioner support (intervention group)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Physician care (control group)
Number of subjects: 788
Study: 19214941

Group type: EXPERIMENTAL
Intervention: BGP-15 200 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: BGP-15 400 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17080881

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (P) at 20 g/mm²
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (P) at 40 g/mm²
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 20 g/mm²
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RU) at 40 g/mm²
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maxcem (M) at 20 g/mm²
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maxcem (M) at 40 g/mm²
Number of subjects: 48
Study: 14732723

Group type: EXPERIMENTAL
Intervention: Low birth weight (<2 kg)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (normal birth weight)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Low birth weight (per kg)
Number of subjects: 168
Study: 11712625

Group type: EXPERIMENTAL
Intervention: Citalopram (specific dosage not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10487593

Group type: EXPERIMENTAL
Intervention: PGG-glucan 0.5 mg/kg
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: PGG-glucan 1.0 mg/kg
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: PGG-glucan (both dosages combined)
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Placebo (noncolorectal stratum)
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: PGG-glucan (combined groups)
Number of subjects: 1249
Study: 7639438

Group type: EXPERIMENTAL
Intervention: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 2654788

Group type: EXPERIMENTAL
Intervention: Combination of recombinant interferon (rIFN) alpha‐2 and chemotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chemotherapy alone (VMCP)
Number of subjects: 52
Study: 19205

Group type: EXPERIMENTAL
Intervention: Tolmetin (1.6 g daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Alclofenac (4 g daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both Tolmetin and Alclofenac
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tolmetin and Alclofenac
Number of subjects: 37
Study: 31064847

Group type: EXPERIMENTAL
Intervention: AT1413 bispecific T-cell-engaging antibody (bTCE)
Number of subjects: 0
Study: 27770480

Group type: EXPERIMENTAL
Intervention: Qualitative somatosensory testing (QualST)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Capsaicin application
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: QualST in AO patients
Number of subjects: 45
Study: 25933402

Group type: EXPERIMENTAL
Intervention: DM-off group (29 eyes)
Number of subjects: 59

Group type: COMPARATOR
Intervention: DM-on group (30 eyes)
Number of subjects: 59
Study: 23822797

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25 μg/day as cholecalciferol tablets)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 21219433

Group type: EXPERIMENTAL
Intervention: Full dose of rapid-acting insulin (mean 7.3±0.2 units)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 75% dose of rapid-acting insulin (mean 5.4±0.1 units)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 50% dose of rapid-acting insulin (mean 3.7±0.1 units)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 25% dose of rapid-acting insulin (mean 1.8±0.1 units)
Number of subjects: 7
Study: 19968379

Group type: EXPERIMENTAL
Intervention: MoodGYM online cognitive behavioral therapy program
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 1477
Study: 17010221

Group type: EXPERIMENTAL
Intervention: 200 mg G115
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 400 mg G115
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (0 mg ginseng and 30 mg saccharin)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ginseng (200 mg ginseng and 30 mg saccharin)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo-glucose (0 mg ginseng and 25 g oral glucose)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ginseng-glucose (200 mg ginseng and 25 g oral glucose)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: G115
Number of subjects: 57
Study: 15463873

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (Immunocal, 10 g twice a day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 21
Study: 10703903

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9515415

Group type: EXPERIMENTAL
Intervention: New Zilactin formula (benzyl alcohol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Old Zilactin formula (tannic acid)
Number of subjects: 10
Study: 8505766

Group type: EXPERIMENTAL
Intervention: Reminder sticker
Number of subjects: 703

Group type: COMPARATOR
Intervention: Control (no reminder sticker)
Number of subjects: 703
Study: 3549844

Group type: EXPERIMENTAL
Intervention: Daily multivitamin supplementation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 29409143

Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg) plus standard therapy
Number of subjects: 268
Study: 27026522

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Number of subjects: 31
Study: 25002832

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: General anaesthesia plus interscalene block
Number of subjects: 83
Study: 22722508

Group type: COMPARATOR
Intervention: Phentermine 45 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phentermine 90 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dronabinol 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Taranabant 4 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Taranabant 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Taranabant (various doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phentermine (various doses)
Number of subjects: 30
Study: 19900726

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP levels in ischemic patients
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP ≥180 pg/ml
Number of subjects: 281
Study: 18272335

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16288148

Group type: EXPERIMENTAL
Intervention: Health education (2 times per week for 8 weeks) and stretching exercises (5 times a week)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 63
Study: 14595277

Group type: EXPERIMENTAL
Intervention: Tongue suspension
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tongue advancement
Number of subjects: 17
Study: 9883861

Group type: EXPERIMENTAL
Intervention: median‐thenar to ulnar‐thenar latency difference (TTLD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: median‐thenar to ulnar‐hypothenar latency difference (THLD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: F‐wave ulnar‐to‐median comparative test (FWLD)
Number of subjects: 50
Study: 8683249

Group type: EXPERIMENTAL
Intervention: GM‐CSF 24 hours before and during chemotherapy (arm +/‐)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GM‐CSF after chemotherapy until day 28 or recovery of PMNs (arm ‐/+)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GM‐CSF before, during, and after chemotherapy (arm +/+)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No GM‐CSF (arm ‐/‐)
Number of subjects: 102
Study: 1906864

Group type: EXPERIMENTAL
Intervention: Twice-daily amikacin (7.5 mg/kg bd) regimen (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Once-daily amikacin (15 mg/kg) schedule (group B)
Number of subjects: 30
Study: 6802391

Group type: EXPERIMENTAL
Intervention: Regimen using simple dietary instructions and laxatives
Number of subjects: 435

Group type: COMPARATOR
Intervention: Preliminary cleansing enema
Number of subjects: 435
Study: 30883050

Group type: EXPERIMENTAL
Intervention: Amlodipine plus Hydrochlorothiazide
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Amlodipine plus Perindopril
Number of subjects: 728

Group type: COMPARATOR
Intervention: Perindopril plus Hydrochlorothiazide
Number of subjects: 728
Study: 29157960

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) inactivated seasonal influenza vaccine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Intramuscular (IM) inactivated seasonal influenza vaccine
Number of subjects: 221
Study: 26002596

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) plus graded exercise therapy
Number of subjects: 296

Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 296
Study: 24374369

Group type: EXPERIMENTAL
Intervention: Functional Capacity Evaluation (FCE)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Functional Interviewing
Number of subjects: 225
Study: 21476931

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 1, 2, and 3 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 182
Study: 19066370

Group type: COMPARATOR
Intervention: Vitamin E (400 IU/d of all rac-alpha-tocopheryl acetate)
Number of subjects: 35533

Group type: COMPARATOR
Intervention: Selenium (200 microg/d from L-selenomethionine)
Number of subjects: 35533

Group type: COMPARATOR
Intervention: Selenium + Vitamin E
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 35533
Study: 17606443

Group type: EXPERIMENTAL
Intervention: Double, intensive treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2 followed by cyclophosphamide 120 mg/kg iv plus total body irradiation 9 Gy and autologous stem cell transplantation)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Single non‐myeloablative treatment (two cycles of non‐myeloablative intermediate‐dose melphalan 70 mg/m2)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Double, intensive treatment
Number of subjects: 303

Group type: COMPARATOR
Intervention: Single non‐myeloablative treatment
Number of subjects: 303
Study: 15172423

Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 104

Group type: COMPARATOR
Intervention: 5 mg amlodipine
Number of subjects: 104
Study: 11393219

Group type: EXPERIMENTAL
Intervention: Buserelin (40 microg in 4 doses i.v. at 12 h intervals)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Buserelin (40 microg in 4 doses i.v.)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Buserelin (4 doses of 20 microg i.v.)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Buserelin (3 doses of 13.3 microg at 6 h interval)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Buserelin treatment
Number of subjects: 5
Study: 9338668

Group type: EXPERIMENTAL
Intervention: Combined filtering surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cataract surgery (phacoemulsification) alone
Number of subjects: 43
Study: 7958517

Group type: EXPERIMENTAL
Intervention: Waterbed group (N = 53)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Mattress group (N = 54)
Number of subjects: 107
Study: 3608590

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 103
Study: 30989419

Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0